Efmoroctocog alfa

Efmoroctocog alfa (INN) is a recombinant factor VIII Fc fusion protein, which is used in the treatment of Hemophilia A. It is a blood clotting factor that is genetically engineered by fusing factor VIII to the Fc portion of immunoglobulin G1. It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line.

Mechanism of Action

Efmoroctocog alfa works by replacing the missing coagulation Factor VIII that the body needs for blood to clot. This helps to prevent and control bleeding episodes in people with Hemophilia A. The Fc portion of the protein helps to extend the half-life of factor VIII, allowing for less frequent dosing than standard factor VIII products.

Medical Uses

Efmoroctocog alfa is used for the control and prevention of bleeding episodes in people with Hemophilia A. It can also be used for perioperative management in these patients. It is suitable for use in adults and children of all ages, including newborns.

Side Effects

Common side effects of Efmoroctocog alfa include headache, dizziness, and rash. Serious side effects may include allergic reactions, which may be life-threatening. The formation of antibodies (inhibitors) against factor VIII is also a potential serious side effect.

History

Efmoroctocog alfa was developed by Biogen Idec and was approved for use in the United States by the Food and Drug Administration (FDA) in 2014. It is marketed under the brand name Eloctate.

See Also

• Hemophilia
• Factor VIII
• Biogen Idec
• Food and Drug Administration

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian